<DOC>
	<DOCNO>NCT00519649</DOCNO>
	<brief_summary>The purpose study assess persistence immunity hepatitis B child receive three consecutive dos HBV vaccine ( EngerixTM-B ) infancy . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Long-term Persistence Immunity Against Hepatitis B 7-8 Years Old Children After Hepatitis B Vaccination .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol . A male female 7 8 year age ( include 7th birthday exclude 9th birthday ) time enrolment . With documented evidence previous vaccination three consecutive dos Engerix™B Germany Written inform consent obtain parent guardian subject time enrolment . Healthy subject establish medical history clinical examination enter study . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product Evidence previous hepatitis B booster vaccination since administration third dose Engerix™B vaccine . History intercurrent hepatitis B disease . Hepatitis B vaccination birth . Planned administration/administration vaccine foreseen study protocol period start 30 day HBV vaccine challenge end 30 day . Administration immunoglobulins and/or blood product within three month precede HBV vaccine challenge plan administration study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior HBV vaccine challenge . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hepatitis B vaccine</keyword>
	<keyword>Challenge dose</keyword>
</DOC>